nach oben

Digestive Diseases and Sciences

Erschienen in:

01.10.2014 | Review

Differential Regulation of EGFR–MAPK Signaling by Deoxycholic Acid (DCA) and Ursodeoxycholic Acid (UDCA) in Colon Cancer

verfasst von: Sara M. Centuori, Jesse D. Martinez

Erschienen in: Digestive Diseases and Sciences | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

A high-fat diet coincides with increased levels of bile acids. This increase in bile acids, particularly deoxycholic acid (DCA), has been strongly associated with the development of colon cancer. Conversely, ursodeoxycholic acid (UDCA) may have chemopreventive properties. Although structurally similar, DCA and UDCA present different biological and pathological effects in colon cancer progression. The differential regulation of cancer by these two bile acids is not yet fully understood. However, one possible explanation for their diverging effects is their ability to differentially regulate signaling pathways involved in the multistep progression of colon cancer, such as the epidermal growth factor receptor (EGFR)–mitogen-activated protein kinase (MAPK) pathway. This review will examine the biological effects of DCA and UDCA on colon cancer development, as well as the diverging effects of these bile acids on the oncogenic signaling pathways that play a role in colon cancer development, with a particular emphasis on bile acid regulation of the EGFR–MAPK pathway.

Enhsen A, Kramer W, Wess GN. Bile acids in drug discovery. Drug Discovery Today. 1998;3:409–418.CrossRef

Hismiogullari AA, Bozdayi AM, Rahman K. Biliary lipid secretion. Turk J Gastroenterol. 2007;18:65–70.PubMed

Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009;50:1509–1520.PubMedPubMedCentralCrossRef

Fukiya S, Arata M, Kawashima H, et al. Conversion of cholic acid and chenodeoxycholic acid into their 7-oxo derivatives by bacteroides intestinalis am-1 isolated from human feces. FEMS Microbiol Lett. 2009;293:263–270.PubMedCrossRef

Odermatt A, Da Cunha T, Penno CA, et al. Hepatic reduction of the secondary bile acid 7-oxolithocholic acid is mediated by 11 beta-hydroxysteroid dehydrogenase 1. Biochem J. 2011;436:621–629.PubMedCrossRef

Powell AA, LaRue JM, Batta AK, Martinez JD. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in hct116 cells. Biochem J. 2001;356:481–486.PubMedPubMedCentralCrossRef

Jean-Louis S, Akare S, Ali MA, Mash EA Jr, Meuillet E, Martinez JD. Deoxycholic acid induces intracellular signaling through membrane perturbations. J Biol Chem. 2006;281:14948–14960.PubMedCrossRef

Martinez JD, Stratagoules ED, LaRue JM, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 1998;31:111–118.PubMedCrossRef

Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group ii phospholipase a2 expression in colonic tissue. Cancer Lett. 1998;134:129–139.PubMedCrossRef

10.

Araki Y, Andoh A, Bamba H, et al. The cytotoxicity of hydrophobic bile acids is ameliorated by more hydrophilic bile acids in intestinal cell lines iec-6 and caco-2. Oncol Rep. 2003;10:1931–1936.PubMed

11.

Cook JW, Kennaway EL, Kennaway NM. Production of tumours in mice by deoxycholic acid. Nature. 1940;145:627.CrossRef

12.

Narisawa T, Magadia NE, Weisburger JH, Wynder EL. Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of n-methyl-n’-nitro-n-nitrosoguanidine in rats. J Natl Cancer Inst. 1974;53:1093–1097.PubMed

13.

Reddy BS, Watanabe K, Weisburger JH, Wynder EL. Promoting effect of bile acids in colon carcinogenesis in germ-free and conventional f344 rats. Cancer Res. 1977;37:3238–3242.PubMed

14.

Reddy BS, Narasawa T, Weisburger JH, Wynder EL. Promoting effect of sodium deoxycholate on colon adenocarcinomas in germfree rats. J Natl Cancer Inst. 1976;56:441–442.PubMed

15.

Ou J, DeLany JP, Zhang M, Sharma S, O’Keefe SJ. Association between low colonic short-chain fatty acids and high bile acids in high colon cancer risk populations. Nutr Cancer. 2012;64:34–40.PubMedCrossRef

16.

Gordon SJ, Miller LJ, Haeffner LJ, Kinsey MD, Kowlessar OD. Abnormal intestinal bile acid distribution in azotaemic man: a possible role in the pathogenesis of uraemic diarrhoea. Gut. 1976;17:58–67.PubMedPubMedCentralCrossRef

17.

Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47:241–259.PubMedCrossRef

18.

Bayerdorffer E, Mannes GA, Richter WO, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology. 1993;104:145–151.PubMed

19.

Ochsenkuhn T, Bayerdorffer E, Meining A, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer. 1999;85:1664–1669.PubMedCrossRef

20.

Bartram HP, Scheppach W, Schmid H, et al. Proliferation of human colonic mucosa as an intermediate biomarker of carcinogenesis: effects of butyrate, deoxycholate, calcium, ammonia, and ph. Cancer Res. 1993;53:3283–3288.PubMed

21.

Deschner EE, Cohen BI, Raicht RF. Acute and chronic effect of dietary cholic acid on colonic epithelial cell proliferation. Digestion. 1981;21:290–296.PubMedCrossRef

22.

McMillan L, Butcher S, Wallis Y, Neoptolemos JP, Lord JM. Bile acids reduce the apoptosis-inducing effects of sodium butyrate on human colon adenoma (aa/c1) cells: implications for colon carcinogenesis. Biochem Biophys Res Commun. 2000;273:45–49.PubMedCrossRef

23.

Earnest DL, Holubec H, Wali RK, et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 1994;54:5071–5074.PubMed

24.

Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889–893.PubMedCrossRef

25.

Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134:89–95.PubMedCrossRef

26.

Alberts DS, Martinez ME, Hess LM, et al. Phase iii trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst. 2005;97:846–853.PubMedCrossRef

27.

Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology. 2003;38:203–209.PubMedCrossRef

28.

Thompson PA, Wertheim BC, Roe DJ, et al. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. Cancer Prev Res (Phila). 2009;2:1023–1030.CrossRef

29.

Gielen J, Van Cantfort J. Role of bile acids in the regulation of cholesterol 7 alpha-hydroxylase. Arch Int Physiol Biochim. 1969;77:965–966.PubMed

30.

Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365.PubMedCrossRef

31.

Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365–1368.PubMedCrossRef

32.

Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor fxr/bar. Mol Cell. 1999;3:543–553.PubMedCrossRef

33.

Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor pxr is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001;98:3369–3374.PubMedPubMedCentralCrossRef

34.

Xie W, Radominska-Pandya A, Shi Y, et al. An essential role for nuclear receptors sxr/pxr in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A. 2001;98:3375–3380.PubMedPubMedCentralCrossRef

35.

Makishima M, Lu TT, Xie W, et al. Vitamin d receptor as an intestinal bile acid sensor. Science. 2002;296:1313–1316.PubMedCrossRef

36.

Logan CY, Nusse R. The wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.PubMedCrossRef

37.

Taketo MM. Shutting down wnt signal-activated cancer. Nat Genet. 2004;36:320–322.PubMedCrossRef

38.

Pai R, Tarnawski AS, Tran T. Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol Biol Cell. 2004;15:2156–2163.PubMedPubMedCentralCrossRef

39.

Wu H, Lin Y, Li W, et al. Regulation of nur77 expression by beta-catenin and its mitogenic effect in colon cancer cells. FASEB J. 2011;25:192–205.PubMedPubMedCentralCrossRef

40.

Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:S9–S15.PubMedCrossRef

41.

Lee HY, Crawley S, Hokari R, Kwon S, Kim YS. Bile acid regulates muc2 transcription in colon cancer cells via positive egfr/pkc/ras/erk/creb, pi3 k/akt/ikappab/nf-kappab and p38/msk1/creb pathways and negative jnk/c-jun/ap-1 pathway. Int J Oncol. 2010;36:941–953.PubMed

42.

Im E, Akare S, Powell A, Martinez JD. Ursodeoxycholic acid can suppress deoxycholic acid-induced apoptosis by stimulating akt/pkb-dependent survival signaling. Nutr Cancer. 2005;51:110–116.PubMedCrossRef

43.

Saeki T, Yui S, Hirai T, Fujii T, Okada S, Kanamoto R. Ursodeoxycholic acid protects colon cancer hct116 cells from deoxycholic acid-induced apoptosis by inhibiting apoptosome formation. Nutr Cancer. 2012;64:617–626.PubMedCrossRef

44.

Raufman JP, Shant J, Guo CY, Roy S, Cheng K. Deoxycholyltaurine rescues human colon cancer cells from apoptosis by activating egfr-dependent pi3 k/akt signaling. J Cell Physiol. 2008;215:538–549.PubMedPubMedCentralCrossRef

45.

Shant J, Cheng K, Marasa BS, Wang JY, Raufman JP. Akt-dependent nf-kappab activation is required for bile acids to rescue colon cancer cells from stress-induced apoptosis. Exp Cell Res. 2009;315:432–450.PubMedPubMedCentralCrossRef

46.

Cheng K, Xie G, Raufman JP. Matrix metalloproteinase-7-catalyzed release of hb-egf mediates deoxycholyltaurine-induced proliferation of a human colon cancer cell line. Biochem Pharmacol. 2007;73:1001–1012.PubMedPubMedCentralCrossRef

47.

Khare S, Mustafi R, Cerda S, et al. Ursodeoxycholic acid suppresses cox-2 expression in colon cancer: roles of ras, p38, and ccaat/enhancer-binding protein. Nutr Cancer. 2008;60:389–400.PubMedCrossRef

48.

Im E, Martinez JD. Ursodeoxycholic acid (udca) can inhibit deoxycholic acid (dca)-induced apoptosis via modulation of egfr/raf-1/erk signaling in human colon cancer cells. J Nutr. 2004;134:483–486.PubMed

49.

Shah SA, Volkov Y, Arfin Q, Abdel-Latif MM, Kelleher D. Ursodeoxycholic acid inhibits interleukin beta 1 and deoxycholic acid-induced activation of nf-κb and ap-1 in human colon cancer cells. Int J Cancer. 2006;118:532–539.PubMedCrossRef

50.

Yoo J, Rodriguez Perez CE, Nie W, Edwards RA, Sinnett-Smith J, Rozengurt E. Tnf-alpha induces upregulation of egfr expression and signaling in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol. 2012;302:G805–G814.PubMedPubMedCentralCrossRef

51.

Hobbs SS, Goettel JA, Liang D, et al. Tnf transactivation of egfr stimulates cytoprotective cox-2 expression in gastrointestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G220–G229.PubMedPubMedCentralCrossRef

52.

Qiao D, Gaitonde SV, Qi W, Martinez JD. Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation. Carcinogenesis. 2001;22:957–964.PubMedCrossRef

53.

Song S, Byrd JC, Koo JS, Bresalier RS. Bile acids induce muc2 overexpression in human colon carcinoma cells. Cancer. 2005;103:1606–1614.PubMedCrossRef

54.

Powell AA, Akare S, Qi W, et al. Resistance to ursodeoxycholic acid-induced growth arrest can also result in resistance to deoxycholic acid-induced apoptosis and increased tumorigenicity. BMC Cancer. 2006;6:219.PubMedPubMedCentralCrossRef

55.

Qiao D, Chen W, Stratagoules ED, Martinez JD. Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase c signaling. J Biol Chem. 2000;275:15090–15098.PubMedCrossRef

56.

Shah SA, Looby E, Volkov Y, Long A, Kelleher D. Ursodeoxycholic acid inhibits translocation of protein kinase c in human colonic cancer cell lines. Eur J Cancer. 2005;41:2160–2169.PubMedCrossRef

57.

Shah SA, Mahmud N, Mftah M, Roche HM, Kelleher D. Chronic but not acute conjugated linoleic acid treatment inhibits deoxycholic acid-induced protein kinase c and nuclear factor-kappab activation in human colorectal cancer cells. Eur J Cancer Prev. 2006;15:125–133.PubMedCrossRef

58.

Qiao L, Studer E, Leach K, et al. Deoxycholic acid (dca) causes ligand-independent activation of epidermal growth factor receptor (egfr) and fast receptor in primary hepatocytes: inhibition of egfr/mitogen-activated protein kinase-signaling module enhances dca-induced apoptosis. Mol Biol Cell. 2001;12:2629–2645.PubMedPubMedCentralCrossRef

59.

Rao YP, Studer EJ, Stravitz RT, et al. Activation of the raf-1/mek/erk cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. Hepatology. 2002;35:307–314.PubMedCrossRef

60.

Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002;122:985–993.PubMedCrossRef

61.

Werneburg NW, Yoon JH, Higuchi H, Gores GJ. Bile acids activate egf receptor via a tgf-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol. 2003;285:G31–G36.PubMed

62.

Yoon JH, Werneburg NW, Higuchi H, et al. Bile acids inhibit mcl-1 protein turnover via an epidermal growth factor receptor/raf-1-dependent mechanism. Cancer Res. 2002;62:6500–6505.PubMed

63.

Goldman A, Chen HD, Roesly HB, et al. Characterization of squamous esophageal cells resistant to bile acids at acidic ph: implication for barrett’s esophagus pathogenesis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G292–G302.PubMedPubMedCentralCrossRef

64.

Avissar NE, Toia L, Hu Y, et al. Bile acid alone, or in combination with acid, induces cdx2 expression through activation of the epidermal growth factor receptor (egfr). J Gastrointest Surg. 2009;13:212–222.PubMedCrossRef

65.

Yasuda H, Hirata S, Inoue K, Mashima H, Ohnishi H, Yoshiba M. Involvement of membrane-type bile acid receptor m-bar/tgr5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun. 2007;354:154–159.PubMedCrossRef

66.

Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogen-activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis. 2001;22:35–41.PubMedCrossRef

67.

Keating N, Mroz MS, Scharl MM, et al. Physiological concentrations of bile acids down-regulate agonist induced secretion in colonic epithelial cells. J Cell Mol Med. 2009;13:2293–2303.PubMedCrossRef

68.

Akare S, Martinez JD. Bile acid induces hydrophobicity-dependent membrane alterations. Biochim Biophys Acta. 2005;1735:59–67.PubMedCrossRef

69.

Rao YP, Stravitz RT, Vlahcevic ZR, Gurley EC, Sando JJ, Hylemon PB. Activation of protein kinase c alpha and delta by bile acids: correlation with bile acid structure and diacylglycerol formation. J Lipid Res. 1997;38:2446–2454.PubMed

70.

Looby E, Long A, Kelleher D, Volkov Y. Bile acid deoxycholate induces differential subcellular localisation of the pkc isoenzymes beta 1, epsilon and delta in colonic epithelial cells in a sodium butyrate insensitive manner. Int J Cancer. 2005;114:887–895.PubMedCrossRef

71.

Fang Y, Han SI, Mitchell C, et al. Bile acids induce mitochondrial ros, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology. 2004;40:961–971.PubMedCrossRef

72.

Cronin J, Williams L, McAdam E, et al. The role of secondary bile acids in neoplastic development in the oesophagus. Biochem Soc Trans. 2010;38:337–342.PubMedCrossRef

73.

Jenkins GJS, D’Souza FR, Suzen SH, et al. Deoxycholic acid at neutral and acid ph, is genotoxic to oesophageal cells through the induction of ROS: the potential role of anti-oxidants in Barrett’s oesophagus. Carcinogenesis. 2006;28:136–142.

74.

Ignacio Barrasa J, Olmo N, Perez-Ramos P, et al. Deoxycholic and chenodeoxycholic bile acids induce apoptosis via oxidative stress in human colon adenocarcinoma cells. Apoptosis. 2011;16:1054–1067.PubMedCrossRef

75.

Feldman R, Martinez JD. Growth suppression by ursodeoxycholic acid involves caveolin-1 enhanced degradation of egfr. Biochim Biophys Acta. 2009;1793:1387–1394.PubMedPubMedCentralCrossRef

76.

Ha YH, Park DG. Effects of dca on cell cycle proteins in colonocytes. J Korean Soc Coloproctol. 2010;26:254–259.PubMedPubMedCentralCrossRef

77.

Mason RP, Moisey DM, Shajenko L. Cholesterol alters the binding of ca2 + channel blockers to the membrane lipid bilayer. Mol Pharmacol. 1992;41:315–321.PubMed

78.

Smith AF, Longpre J, Loo G. Inhibition by zinc of deoxycholate-induced apoptosis in hct-116 cells. J Cell Biochem. 2012;113:650–657.PubMedCrossRef

79.

Longpre J, Loo G. Inhibition of deoxycholate-induced apoptosis in iron-depleted hct-116 cells. Apoptosis. 2012;17:70–78.PubMedCrossRef

80.

Di Toro R, Campana G, Murari G, Spampinato S. Effects of specific bile acids on c-fos messenger rna levels in human colon carcinoma caco-2 cells. Eur J Pharm Sci. 2000;11:291–298.PubMedCrossRef

81.

Kim HS, Lee YK, Kim JW, Baik SK, Kwon SO, Jang HI. Modulation of colon cancer cell invasiveness induced by deoxycholic acid. Korean J Gastroenterol. 2006;48:9–18.PubMed

82.

Lee DK, Park SY, Baik SK, et al. Deoxycholic acid-induced signal transduction in ht-29 cells: role of nf-kappa b and interleukin-8. Korean J Gastroenterol. 2004;43:176–185.PubMed

83.

Zeng H, Botnen JH, Briske-Anderson M. Deoxycholic acid and selenium metabolite methylselenol exert common and distinct effects on cell cycle, apoptosis, and map kinase pathway in hct116 human colon cancer cells. Nutr Cancer. 2009;62:85–92.CrossRef

84.

McMillan L, Butcher SK, Pongracz J, Lord JM. Opposing effects of butyrate and bile acids on apoptosis of human colon adenoma cells: differential activation of pkc and map kinases. Br J Cancer. 2003;88:748–753.PubMedPubMedCentralCrossRef

85.

Krishna-Subramanian S, Hanski ML, Loddenkemper C, et al. Udca slows down intestinal cell proliferation by inducing high and sustained erk phosphorylation. Int J Cancer. 2012;130:2771–2782.PubMedCrossRef

86.

Miyaki A, Yang P, Tai H-H, Subbaramaiah K, Dannenberg AJ. Bile acids inhibit nad + -dependent 15-hydroxyprostaglandin dehydrogenase transcription in colonocytes. Am J Physiol Gastrointest Liver Physiol. 2009;297:G559–G566.PubMedPubMedCentralCrossRef

87.

Merchant NB, Rogers CM, Trivedi B, Morrow J, Coffey RJ. Ligand-dependent activation of the epidermal growth factor receptor by secondary bile acids in polarizing colon cancer cells. Surgery. 2005;138:415–421.PubMedCrossRef

88.

Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD. Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int J Cancer. 2006;119:2958–2969.PubMedCrossRef

89.

Da Silva M, Jaggers GK, Verstraeten SV, Erlejman AG, Fraga CG, Oteiza PI. Large procyanidins prevent bile-acid-induced oxidant production and membrane-initiated erk1/2, p38, and akt activation in caco-2 cells. Free Radic Biol Med. 2012;52:151–159.PubMedCrossRef

Titel: Differential Regulation of EGFR–MAPK Signaling by Deoxycholic Acid (DCA) and Ursodeoxycholic Acid (UDCA) in Colon Cancer
verfasst von: Sara M. Centuori
Jesse D. Martinez
Publikationsdatum: 01.10.2014
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 10/2014
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-014-3190-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Accuracy of Diagnostic Codes for Identifying Patients with Ulcerative Colitis and Crohn’s Disease in the Veterans Affairs Health Care System

Effect of Follow-Up Endoscopy on the Outcomes of Patients with Inflammatory Bowel Disease

Characterization of the Syndrome of UGI Bleeding from a Mallory-Weiss Tear Associated with Transesophageal Echocardiography

Endoscopic Resection for Undifferentiated Early Gastric Cancer: Focusing on Histologic Discrepancies Between Forceps Biopsy-Based and Endoscopic Resection Specimen-Based Diagnosis

White Opaque Substance Visualized Using Magnifying Endoscopy with Narrow-Band Imaging in Colorectal Epithelial Neoplasms